Roflumilast Tablet
Product Images NDC 73190-086

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Roflumilast (NDC 73190-086). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (086 28)

Packaging label for Roflumilast Tablets 250 mcg oral tablets, 28 day pack, manufactured by CorePharma, LLC for AvKARE. The label includes dosing instructions, storage information, a barcode, and warns to dispense the medication guide to patients. The design features white background with blue and red text highlights.*

FDA Label Image

1 (087 30)

Label for AvKARE Roflumilast Tablets, 500 mcg oral tablets. The label specifies the pharmacist should dispense the Medication Guide separately to patients. Each tablet contains 500 mcg roflumilast, with a total of 30 tablets in the package. The label includes the NDC 73190-087-30 and manufacturer details for Corbin Pharma, LLC.*

FDA Label Image

1 (087 90)

The packaging label for roflumilast tablets by AvKARE displays the 500 mcg oral tablet strength. The label includes the NDC number 73190-087-90, with a quantity of 90 tablets. It notes the pharmacist dispensing instructions, batch information, manufacturer details, and expiration date.*

FDA Label Image

Structure (3f5bf140 40c1 4555 9ca1 7c74a444424a 01)

Chemical structure of roflumilast, the active ingredient in the prescription drug roflumilast tablets. The diagram shows the molecular arrangement including fluorine atoms, a cyclopropyl group, and chlorine-substituted pyridine ring.*

FDA Label Image

Figure 1 (3f5bf140 40c1 4555 9ca1 7c74a444424a 02)

A forest plot chart illustrating the fold change in maximum concentration (Cmax) and area under the curve (AUC) of Roflumilast and its N-oxide metabolite relative to reference when combined with various drugs. The chart includes drugs like Cimetidine, Enoxacin, and Ketoconazole with recommendations for use with caution, and others like Budesonide and Warfarin that require no dose adjustment. Rifampicin is noted as not recommended.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.